ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In vitro, we investigated the ability of CRISPR/Cas9/dual-sgRNA to disrupt theBCR-ABL oncogene and its effect on CML cell lines and primary cells isolated from patients with CML and explored its effect in a xenograft CML model.